Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1981 May;73(1):55–64. doi: 10.1111/j.1476-5381.1981.tb16771.x

Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B.

A Kalir, A Sabbagh, M B Youdim
PMCID: PMC2071835  PMID: 7284698

Abstract

1 A number of aromatic-N-propargyl (acetylenic) compounds and indoleamines were tested for their inhibitory action on monoamine oxidase (MAO) type A and type B using the substrates 5-hydroxytryptamine (5-HT), beta-phenylethylamine (PEA) and dopamine. 2 Structure activity studies with aromatic-N-propragyl (acetylenic) derivatives have shown that MAO inhibitory potency is least dependent on the aromatic portion of the compounds. N-methylated propargyl derivatives are the most active and replacement of the methyl group with a higher alkyl or aromatic group results in significant reduction of activity. The triple bond in the N-propargyl portion is absolutely essential for activity and must be beta-to the nitrogen. It is the acetylenic group that gives these compounds their irreversible MAO inhibitory property. 3 The present study has indicated that since the acetylenic compounds resemble the enzyme substrates the distance between the aromatic ring and the N-propargyl terminal is crucial in designating the type A or type B MAO inhibitory property. For MAO type A inhibition, a distance equivalent to at least three carbon units is required, while for the inhibition of the B type enzyme this distance can be 1 or 2 carbon units. 4 The compounds AGN-1133 and AGN-1135 show most promise in Parkinson's disease or as anti-depressants because of their irreversible selective type B MAO inhibition in vitro and in vivo. 5 A number of indoleamine derivatives were found to be reversible selective type A inhibitors.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birkmayer W., Riederer P., Ambrozi L., Youdim M. B. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1977 Feb 26;1(8009):439–443. doi: 10.1016/s0140-6736(77)91940-7. [DOI] [PubMed] [Google Scholar]
  2. Birkmayer W., Riederer P., Youdim M. B., Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm. 1975;36(3-4):303–326. doi: 10.1007/BF01253131. [DOI] [PubMed] [Google Scholar]
  3. Elsworth J. D., Glover V., Reynolds G. P., Sandler M., Lees A. J., Phuapradit P., Shaw K. M., Stern G. M., Kumar P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) 1978 Apr 14;57(1):33–38. doi: 10.1007/BF00426954. [DOI] [PubMed] [Google Scholar]
  4. Finberg J. P., Tenne M., Youdim M. B. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981 May;73(1):65–74. doi: 10.1111/j.1476-5381.1981.tb16772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Glover V., Sandler M., Owen F., Riley G. J. Dopamine is a monoamine oxidase B substrate in man. Nature. 1977 Jan 6;265(5589):80–81. doi: 10.1038/265080a0. [DOI] [PubMed] [Google Scholar]
  6. Green A. R., Youdim M. B. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol. 1975 Nov;55(3):415–422. doi: 10.1111/j.1476-5381.1975.tb06946.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. HAWKINS J. The localization of amine oxidase in the liver cell. Biochem J. 1952 Mar;50(5):577–581. doi: 10.1042/bj0500577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Houslay M. D., Tipton K. F. A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes. Biochem J. 1974 Jun;139(3):645–652. doi: 10.1042/bj1390645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnston J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968 Jul;17(7):1285–1297. doi: 10.1016/0006-2952(68)90066-x. [DOI] [PubMed] [Google Scholar]
  10. KALIR A., SZARA S. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF FLUORINATED TRYPTAMINE DERIVATIVES. J Med Chem. 1963 Nov;6:716–719. doi: 10.1021/jm00342a019. [DOI] [PubMed] [Google Scholar]
  11. Kalir A., Szara S. Synthesis and pharmacological activity of alkylated tryptamines. J Med Chem. 1966 May;9(3):341–344. doi: 10.1021/jm00321a017. [DOI] [PubMed] [Google Scholar]
  12. Knoll J., Ecsery Z., Magyar K., Sátory E. Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem Pharmacol. 1978;27(13):1739–1747. doi: 10.1016/0006-2952(78)90550-6. [DOI] [PubMed] [Google Scholar]
  13. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408. [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Mann J., Gershon S. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci. 1980 Mar 17;26(11):877–882. doi: 10.1016/0024-3205(80)90350-1. [DOI] [PubMed] [Google Scholar]
  16. Mantle T. J., Tipton K. F. Monoamine oxidase A and B: a useful concept? Biochem Pharmacol. 1978 Jan 1;27(1):97–101. doi: 10.1016/0006-2952(78)90262-9. [DOI] [PubMed] [Google Scholar]
  17. Mendlewicz J., Youdim M. B. Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor. J Neural Transm. 1978;43(3-4):279–286. doi: 10.1007/BF01246965. [DOI] [PubMed] [Google Scholar]
  18. Reynolds G. P., Elsworth J. D., Blau K., Sandler M., Lees A. J., Stern G. M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol. 1978 Dec;6(6):542–544. doi: 10.1111/j.1365-2125.1978.tb00883.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Riederer P., Youdim M. B., Rausch W. D., Birkmayer W., Jellinger K., Seemann D. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm. 1978;43(3-4):217–226. doi: 10.1007/BF01246958. [DOI] [PubMed] [Google Scholar]
  20. SWETT L. R., MARTIN W. B., TAYLOR J. D., EVERETT G. M., WYKES A. A., GLADISH Y. C. Structure-activity relations in the pargyline series. Ann N Y Acad Sci. 1963 Jul 8;107:891–898. doi: 10.1111/j.1749-6632.1963.tb13332.x. [DOI] [PubMed] [Google Scholar]
  21. Salach J. I., Detmer K., Youdim M. B. The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl. Mol Pharmacol. 1979 Jul;16(1):234–241. [PubMed] [Google Scholar]
  22. Squires R. F. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol. 1972;5:355–370. [PubMed] [Google Scholar]
  23. Teller D. N., De Guzman T., Lajtha A. Factors affecting morphine uptake into kidney slices. Biochem Pharmacol. 1976 Jun 1;25(11):1271–1284. doi: 10.1016/0006-2952(76)90090-3. [DOI] [PubMed] [Google Scholar]
  24. Yahr M. D. Overview of present day treatment of Parkinson's disease. J Neural Transm. 1978;43(3-4):227–238. doi: 10.1007/BF01246959. [DOI] [PubMed] [Google Scholar]
  25. Yang H. Y., Neff N. H. Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain. J Pharmacol Exp Ther. 1973 Nov;187(2):365–371. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES